281 related articles for article (PubMed ID: 17277134)
21. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD.
Villunger A; Huang DC; Holler N; Tschopp J; Strasser A
J Immunol; 2000 Aug; 165(3):1337-43. PubMed ID: 10903735
[TBL] [Abstract][Full Text] [Related]
22. B cell receptor cross-linking triggers a caspase-8-dependent apoptotic pathway that is independent of the death effector domain of Fas-associated death domain protein.
Besnault L; Schrantz N; Auffredou MT; Leca G; Bourgeade MF; Vazquez A
J Immunol; 2001 Jul; 167(2):733-40. PubMed ID: 11441077
[TBL] [Abstract][Full Text] [Related]
23. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis.
Wang P; Song JH; Song DK; Zhang J; Hao C
Cell Signal; 2006 Sep; 18(9):1528-35. PubMed ID: 16442262
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of Fas-associated death domain-like IL-1-converting enzyme (FLICE)-inhibitory protein induces resistance to Fas-mediated apoptosis in activated mast cells.
Yoshikawa H; Nakajima Y; Tasaka K
J Immunol; 2000 Dec; 165(11):6262-9. PubMed ID: 11086061
[TBL] [Abstract][Full Text] [Related]
25. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
26. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells.
Eeva J; Nuutinen U; Ropponen A; Mättö M; Eray M; Pellinen R; Wahlfors J; Pelkonen J
Apoptosis; 2009 May; 14(5):687-98. PubMed ID: 19308735
[TBL] [Abstract][Full Text] [Related]
27. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs.
Micheau O; Solary E; Hammann A; Dimanche-Boitrel MT
J Biol Chem; 1999 Mar; 274(12):7987-92. PubMed ID: 10075697
[TBL] [Abstract][Full Text] [Related]
28. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.
Shain KH; Landowski TH; Dalton WS
J Immunol; 2002 Mar; 168(5):2544-53. PubMed ID: 11859150
[TBL] [Abstract][Full Text] [Related]
29. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
An S; Yap D; Knox KA
Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
[TBL] [Abstract][Full Text] [Related]
30. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
[TBL] [Abstract][Full Text] [Related]
31. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
Yang BF; Xiao C; Li H; Yang SJ
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
[TBL] [Abstract][Full Text] [Related]
32. Actinomycin D-mediated sensitization of AIDS-Kaposi's sarcoma cells to Fas-mediated apoptosis: involvement of the mitochondrion-dependent pathway.
Mori S; Murakami-Mori K; Nakamura S; Bonavida B
Int J Oncol; 2002 Apr; 20(4):819-26. PubMed ID: 11894131
[TBL] [Abstract][Full Text] [Related]
33. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.
Gajate C; Gonzalez-Camacho F; Mollinedo F
PLoS One; 2009; 4(4):e5044. PubMed ID: 19352436
[TBL] [Abstract][Full Text] [Related]
34. Fas-associated death domain protein is a Fas-mediated apoptosis modulator in synoviocytes.
Okamoto K; Kobayashi T; Kobata T; Hasunuma T; Kato T; Sumida T; Nishioka K
Rheumatology (Oxford); 2000 May; 39(5):471-80. PubMed ID: 10852976
[TBL] [Abstract][Full Text] [Related]
35. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
[TBL] [Abstract][Full Text] [Related]
37. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Gajate C; Mollinedo F
Blood; 2007 Jan; 109(2):711-9. PubMed ID: 17003375
[TBL] [Abstract][Full Text] [Related]
38. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
39. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
40. Efficient recruitment of c-FLIP
Masuda A; Isobe Y; Sugimoto K; Yoshimori M; Arai A; Komatsu N
Cancer Sci; 2020 Mar; 111(3):807-816. PubMed ID: 31908105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
